LLY Stock Jumps as Q3 Earnings Beat Estimates, 2026 Sales View Raised

Eli Lilly reported Q3 2026 adjusted EPS of $7.48, 39% above the $5.38 consensus, and revenue of $24.40 billion, up 39% year over year and 10.4% above estimates. Mounjaro sales rose 65% to $10.72 billion and Zepbound gained 49% to $5.35 billion; Lilly raised 2026 revenue guidance to $91-$92 billion from $85-$87 billion, while lowering its adjusted EPS outlook to $35-$36 from $35.50-$36.50. Shares rose around 4% in pre-market trading; some established drugs missed estimates or declined, and one-time items also supported quarterly revenue.

Analysis

The key signal is conversion quality, not the headline beat: volume growth is outrunning revenue growth while realized prices fall, so continued top-line acceleration may require sustained patient uptake and supply rather than pricing power. Lower prices in China following reimbursement inclusion illustrate the trade-off: broader access can expand units while diluting revenue per unit. With GLP-1s representing roughly 65% of sales, any supply, access, or competitive disruption has outsized earnings leverage despite newer-drug diversification.

The guidance increase is not a clean EPS upgrade. Underlying growth was offset by acquired IPR&D charges, and reported quarterly sales also benefited from milestones and favorable rebate-estimate adjustments. Separate recurring demand from these items before extrapolating the quarter. The lower EPS range alongside higher revenue guidance raises the importance of margins, launch investment, and deal-related costs—not just sales momentum.

Near term, the pre-market reaction risks pricing in a strong quarter before investors see the durability of price/volume and net pricing. NVO’s Nov. 4 results are the next direct read-through on oral GLP-1 uptake and competitive positioning. Over 6–18 months, oral adoption and Lilly’s pipeline could broaden the market, but could also intensify price competition and cannibalization; current data do not establish the economics of either. Falsifiers for the bullish thesis: decelerating GLP-1 volumes, further net-price erosion that overwhelms units, or guidance/margins weakening after one-time benefits roll off. ATAI-related IPR&D charges should not be read as evidence of operating traction for ATAI; deal economics are not provided.

Key Decisions for Investors

• LLY: Avoid chasing the pre-market gap. Consider adding only after the event reaction settles and management confirms sustained volume growth without materially worsening net-price trends; reduce exposure if subsequent guidance or margins imply price erosion is outrunning units.
• NVO: Treat Nov. 4 as a catalyst, not a predetermined short. Track oral-product uptake, supply/access commentary, and pricing; a relative LLY-long/NVO-short is only a tactical, small-sized expression if NVO data show weaker execution, and should be reconsidered if both companies report broadening demand without worsening pricing.
• For the next 1–3 months, monitor the bridge from volume to net sales and strip out milestone/rebate benefits when assessing run-rate growth. A deterioration in that bridge would invalidate the market’s volume-led growth premium; continued price resilience would support it.
• ATAI: No directional trade from this report. Verify transaction terms and the nature/timing of the IPR&D charge before drawing any conclusion about value accruing to ATAI shareholders.